Zentalis appoints Hausman as CMO, Rasbach as CBO

Zentalis Pharmaceuticals (ZNTL) announced that Diana Hausman, M.D., a member of Zentalis’ Board of Directors, was appointed as Chief Medical Officer, CMO, and Kyle Rasbach, Ph.D., Pharm.D., was appointed as Chief Business Officer, CBO. Dr. Hausman is an oncologist with over a decade of experience as a Chief Medical Officer, having previously served in the role at Link Immunotherapeutics, Lengo Therapeutics, Zymeworks (ZYME), and Oncothyreon. Dr. Hausman will succeed Carrie Brownstein, M.D., who is stepping down for personal reasons. Dr. Brownstein will remain with Zentalis as a consultant for a transitional period. Dr. Rasbach comes to Zentalis from Eventide Asset Management, where he was a Portfolio Manager for Eventide’s healthcare and life sciences strategies, a Managing Director for Eventide Ventures, and a Senior Research Analyst for other Eventide investments.